Should a neck dissection be performed on patients with cN0 adenoid cystic carcinoma? A REFCOR propensity score matching study.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
05 2020
Historique:
received: 29 09 2019
revised: 17 11 2019
accepted: 26 12 2019
pubmed: 6 2 2020
medline: 10 4 2021
entrez: 4 2 2020
Statut: ppublish

Résumé

Patterns of nodal involvement in adenoid cystic carcinoma (ACC) of the head and neck have not been sufficiently assessed to guide a decision of prophylactic neck dissection (ND). The objective of this study is to analyse the influence of ND on event-free survival (EFS) for patients with cN0 ACC. A multicentre prospective study was conducted between 2009 and 2018. Patients presenting cN0 non-metastatic ACC on any site, and who received surgery on the tumour, were included. EFS was the main judgement criterion. A comparative survival analysis between the groups that received a ND versus those that did not was performed, using a propensity score. Analyses were carried out using the R software. Between 2009 and 2018, 322 patients with cN0 ACC were included, out of which 58% were female. The average age was 53 years. Tumours were in minor salivary glands in 58% of cases, and 52% had T3/T4 stages. ND was performed on 46% of patients. Out of them, seven had histological lymph node invasion, out of which six had tumour infiltration in the mucosa of oral cavity. After propensity score, the median EFS for N0 patients with ND was 72 months (95% Confidence Interval (CI) [48-81]), compared to 73 months (95% CI [52-85]) for patients without ND (HR = 1.33; 95% CI [0.82-2.16]; p = 0.2). ND of cN0 patients does not provide any benefit on EFS, which suggests that its application on such patients is not necessary.

Sections du résumé

BACKGROUND
Patterns of nodal involvement in adenoid cystic carcinoma (ACC) of the head and neck have not been sufficiently assessed to guide a decision of prophylactic neck dissection (ND). The objective of this study is to analyse the influence of ND on event-free survival (EFS) for patients with cN0 ACC.
PATIENTS AND METHODS
A multicentre prospective study was conducted between 2009 and 2018. Patients presenting cN0 non-metastatic ACC on any site, and who received surgery on the tumour, were included. EFS was the main judgement criterion. A comparative survival analysis between the groups that received a ND versus those that did not was performed, using a propensity score. Analyses were carried out using the R software.
RESULTS
Between 2009 and 2018, 322 patients with cN0 ACC were included, out of which 58% were female. The average age was 53 years. Tumours were in minor salivary glands in 58% of cases, and 52% had T3/T4 stages. ND was performed on 46% of patients. Out of them, seven had histological lymph node invasion, out of which six had tumour infiltration in the mucosa of oral cavity. After propensity score, the median EFS for N0 patients with ND was 72 months (95% Confidence Interval (CI) [48-81]), compared to 73 months (95% CI [52-85]) for patients without ND (HR = 1.33; 95% CI [0.82-2.16]; p = 0.2).
CONCLUSION
ND of cN0 patients does not provide any benefit on EFS, which suggests that its application on such patients is not necessary.

Identifiants

pubmed: 32008920
pii: S0959-8049(19)30894-9
doi: 10.1016/j.ejca.2019.12.026
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

250-258

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement The authors have declared no conflict of interest.

Auteurs

Sarah Atallah (S)

Sorbonne University, APHP, Department of ENT-Head and Neck Surgery, Tenon Hospital, 4 rue de la chine, 75020, Paris, France; Doctoral School of Public Health, CESP, University of Paris Sud, 16 Avenue Paul Vaillant Couturier, 94807, Villejuif, France.

Antoine Moya-Plana (A)

Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, 114, rue Edouard Vaillant, 94805, Villejuif, France.

Olivier Malard (O)

Department of ENT-Head and Neck Surgery, Nantes University Hospital, 1 Place Alexis-Ricordeau, 44000, Nantes, France.

Gilles Poissonnet (G)

Department of ENT-Head and Neck Surgery, Centre Antoine-Lacassagne-IUFC, 31 Avenue de Valombrose, 06189, Nice, France.

Nicolas Fakhry (N)

Department of ENT-Head and Neck Surgery, University Hospital of Marseille, APHM, 13915, Marseille, France.

Jérémie Bettoni (J)

Department of Maxillofacial Surgery, University Hospital of Amiens-Picardy, Avenue René Laennec, 80000, Amiens, France.

Patrice Gallet (P)

Department of ENT-Head and Neck Surgery, Regional University Hospital of Nancy, Hospital of Brabois, 54035, Nancy, France.

Pierre Ransy (P)

Department of ENT-Head and Neck Surgery, University Hospital of Liège, Belgium.

Sebastien Vergez (S)

Department of ENT-Head and Neck Surgery, University Cancer Institute Toulouse, Toulouse University Hospital, 1 avenue Irène Joliot-Curie, 31400, Toulouse, France.

Ludovic De Gabory (L)

Department of ENT-Head and Neck Surgery, University Hospital of Bordeaux, Hôpital Pellegrin, Centre Michelet, Place Amélie Raba-Léon, 33076, Bordeaux, France.

Diane Evrard (D)

Department of ENT-Head and Neck Surgery, Hospital Bichat, APHP, 75018, Paris, France.

Maria Lesnik (M)

Department of ENT-Head and Neck Surgery, Curie Institute, 26 rue d'Ulm, 75005, Paris, France.

Pierre Philouze (P)

Department of ENT-Head and Neck Surgery, Hospices Civils de Lyon, Lyon-Nord University Hospital, 103 Grande Rue de la Croix Rousse, 69000, Lyon, France.

Chloé Bertolus (C)

Department of Oral and Maxillofacial Surgery, Sorbonne University, Pitié-Salpétrière Hospital, APHP, 75013, Paris, France.

Philippe Schultz (P)

Department of ENT-Head and Neck Surgery, University Hospital of Strasbourg, 67000, Strasbourg, France.

Sylvain Morinière (S)

Department of ENT-Head and Neck Surgery, Tours Bretonneau University Hospital, 2 Boulevard Tonnellé, 37000, Tours, France.

Vianney Bastit (V)

Department of ENT-Head and Neck Surgery, François Baclesse Centre, 3 rue du Général Harris, 14000, Caen, France.

Christian A Righini (CA)

Department of ENT-Head and Neck Surgery, Grenoble Alpes University Hospital, CS 10217, 38043, Grenoble, France.

Haitham Mirghani (H)

Department of ENT-Head and Neck Surgery, Georges Pompidou European Hospital, AP-HP, 20, rue Leblanc, 75015, Paris, France.

Franck Jegoux (F)

Department of ENT-Head and Neck Surgery, Rennes University Hospital, 2 Rue Henri Le Guilloux, 35000, Rennes, France.

Olivier Mauvais (O)

Department of ENT-Head and Neck Surgery, University Hospital of Besançon, France, 25000, Besançon, France.

Julian Biau (J)

Department of Radiotherapy, Jean Perrin Centre, University Clermont Auvergne, 63100, Clermont-Ferrand, France.

Xavier Dufour (X)

Department of ENT-Head and Neck and Maxillofacial Surgery, University Hospital of Poitiers, 2 Rue de la Milétrie, CS 90577, 86021, Poitiers, France.

Nicolas Bon-Mardion (N)

Department of ENT-Head and Neck Surgery, Rouen University Hospital, 1 rue de Germont, 76031, Rouen, France.

Esteban Brenet (E)

Department of ENT-Head and Neck Surgery, Robert Debré University Hospital, Reims, France.

Benjamin Verillaud (B)

Department of ENT-Head and Neck Surgery, Lariboisière University Hospital,INSERM U1141, Paris Diderot University, APHP, 75010, Paris, France.

Bertrand Baujat (B)

Sorbonne University, APHP, Department of ENT-Head and Neck Surgery, Tenon Hospital, 4 rue de la chine, 75020, Paris, France. Electronic address: bertrand.baujat@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH